ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer.

BACKGROUND

The Laparoscopic Approach to Cervical Cancer trial is the only randomized trial to date addressing the role of surgical approach in cervical cancer; however, this non-inferiority trial of minimally invasive surgery vs an open approach in patients undergoing radical hysterectomy for early-stage cervical cancer did not meet its primary end point of 4.5-year disease-free survival and was terminated early because of significantly worse disease-specific survival, overall survival, and locoregional recurrence in the minimally invasive surgery cohort.

PRIMARY

OBJECTIVE

Our trial compares 3-year disease-free survival after robotic-assisted or abdominal radical or simple (in select cases) hysterectomy in early-stage cervical cancer.

STUDY HYPOTHESIS: We hypothesize that disease-free survival is non-inferior after robotic-assisted vs abdominal radical or simple hysterectomy.

TRIAL

DESIGN

This multi-center, randomized non-inferiority trial conducted through the Gynecologic Oncology Group has specified surgeon qualification criteria. It requires a pelvic magnetic resonance imaging scan in all patients before enrollment and will use 1:1 randomization to assign patients to robotic-assisted or abdominal hysterectomy. All surgeons must use specified tumor-containment techniques in both arms. It does not allow trans-cervical uterine manipulators.

MAJOR INCLUSION/EXCLUSION CRITERIA: Patients with early-stage (2018 International Federation of Gynecology and Obstetrics stages IA2-IB2) cervical cancer. Histologic types are limited to squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. Pelvic magnetic resonance imaging must confirm a tumor that is 4 cm or less without definitive extra-cervical spread. A simple hysterectomy is allowed in select cases after trial study principal investigator review.

PRIMARY ENDPOINT: The primary end point is the 3-year disease-free survival between robotic-assisted or abdominal hysterectomy.

SAMPLE SIZE: The trial will randomly allocate 840 patients, with planned interim analysis for futility (oncologic safety) after we have randomly allocated 370 and 640 patients.

ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING

RESULTS

2030.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04831580.